Tasly Receives Approvals For Transaction With MSB
Filed with ASX · · 1 page · English
Earlier from Mesoblast
- Mesoblast Reports on Annual and Fourth Quarter Results
- Update on Tasly transaction
- MSB Enters Into Cardiovascular Alliance For China With Tasly
- MSB Enters Into US$50M Financing With NovaQuest Capital
- Key Day 100 Survival Results In P3 GvHD Trial
Later from Mesoblast
- Day 180 Survival Outcomes In aGvHD Phase 3 Trial
- Completion of Tasly Transaction, and Appendix 3B
- MSB Expands Partnership With JCR For Skin Disease
- LVAD Trial Results Provide Potential Regulatory Pathway
- LVAD Results Webcast Presentation
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast